Onesource Specialty Pharma

Onesource Specialty Pharma Dividend Coverage

Dividend Coverage Ratio of Onesource Specialty Pharma (ONESOURCE.NS) as of Oct 19, 2026.

Dividend Coverage

-

Last updated:

Dividend Coverage Ratio of Onesource Specialty Pharma is 2026 - . Dividend Coverage Ratio of Onesource Specialty Pharma was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Onesource Specialty Pharma Stock analysis

What does Onesource Specialty Pharma do? Onesource Specialty Pharma Ltd, headquartered in Bangalore, India, operates in the Health Care sector within the Life Sciences Tools & Services industry. The company, listed on 24 January 2025, employs 525 full-time staff and functions as a vertically integrated biopharma CDMO. It specializes in developing and manufacturing complex biologics, biosimilars, and vaccines, with expertise in prefilled syringes, autoinjectors, and advanced delivery systems for cell and gene therapies and RNA products. Its integrated services support comprehensive biologics development and production. Onesource Specialty Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Onesource Specialty Pharma stock

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Onesource Specialty Pharma since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Onesource Specialty Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Onesource Specialty Pharma

All Key Metrics — Onesource Specialty Pharma